Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
Scandinavian journal of gastroenterology（2022）
摘要
Immunogenicity to anti-TNFs does not influence treatment persistence of subsequent ustekinumab and vedolizumab therapy.
更多查看译文
关键词
Crohn’s disease,Inflammatory bowel disease,anti-TNF,immunogenicity,ulcerative colitis,ustekinumab,vedolizumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要